SB 5204
In CommitteeSenate
Ibogaine-assisted therapy
Concerning ibogaine-assisted therapy.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires the University of Washington to conduct a three-year study comparing ibogaine-assisted therapy (administered in Mexico with follow-up support) to standard U.S. treatments for opioid use disorder. It includes legislative findings highlighting ibogaine’s potential as a rapid-acting, life-saving treatment and prior state research showing low cardiac risk in medical settings.
- Directs the University of Washington to conduct a three-year, prospective, randomized cohort study comparing ibogaine-assisted therapy (administered in a licensed clinic in Mexico, followed by structured therapeutic support) to standard U.S. treatments (medication-assisted treatment and psychotherapy) for adults with opioid use disorder.
- Requires the study to measure outcomes such as treatment engagement, reduction in opioid use, mortality, functional status, craving, motivation to change, and self-efficacy, using validated tools and research methods.
- Includes legislative findings recognizing ibogaine’s potential to rapidly reduce withdrawal symptoms and cravings after a single dose, and notes prior state-funded research showing low cardiac risk when used in medical settings.
- Aims to fill a critical research gap due to ibogaine’s Schedule I status, which has limited U.S. research despite its promising therapeutic potential.
Who is affected
- Adults with opioid use disorder — Adults with opioid use disorder may gain access to a potentially more effective treatment option if the study shows strong benefits and leads to expanded clinical use.
- Healthcare providers treating addiction — May benefit from new evidence supporting safer, more effective treatment pathways, especially for those who do not respond well to current therapies like methadone or buprenorphine.
- University of Washington — Will conduct and manage the three-year study, including participant recruitment, data collection, and analysis.
- State government agencies (e.g., Department of Health, Department of Licensing) — May see increased research activity and potential policy changes if the study yields positive results, influencing future funding and regulatory decisions.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (4)
This study could generate high-impact evidence on ibogaine’s efficacy and safety for opioid use disorder—a condition with high mortality and limited long-term treatment success—potentially leading to a paradigm shift in addiction care and life-saving interventions for people who have not responded to standard therapies.
HealthcarePeopleRef: Sec. 1(1), Sec. 2(1)The bill builds on prior state-funded cardiac safety research, indicating Washington has already begun de-risking ibogaine; this study leverages that foundation to test real-world outcomes, potentially accelerating clinical adoption and expanding treatment options for underserved patients with treatment-resistant addiction.
HealthcarePeopleRef: Sec. 1(3), Sec. 2(2)By rigorously evaluating ibogaine in a real-world setting, the study may reduce opioid-related overdoses, crime, and emergency service use—yielding downstream public safety and criminal justice system benefits for communities disproportionately affected by the opioid crisis.
Public SafetyPeopleRef: Sec. 2(2)The University of Washington will develop expertise in advanced addiction research methodology and international clinical trial coordination, strengthening academic capacity and training the next generation of researchers in innovative public health approaches.
EducationLean peopleRef: Sec. 2(1)
Potential Concerns (4)
The study design requires participants to travel to Mexico for ibogaine administration, which introduces significant logistical, financial, and safety barriers—particularly for low-income, uninsured, or undocumented individuals—limiting equitable access to participation and potentially excluding the most vulnerable populations who may benefit most.
HealthcarePeopleRef: Sec. 2(1)Administering ibogaine outside the U.S. regulatory framework (i.e., in Mexico) bypasses FDA oversight and U.S. clinical trial safety standards, raising concerns about inconsistent medical screening, adverse event reporting, and long-term monitoring—potentially exposing participants to unquantified risks.
Public SafetyLean peopleRef: Sec. 2(1)The study relies on existing state funds previously allocated for cardiac safety research, meaning it repurposes limited public health research dollars rather than expanding capacity—diverting resources from other high-need addiction research or direct service delivery without new investment.
HealthcareLean peopleRef: Fiscal Impact (no new appropriation)While the bill seeks to overcome Schedule I restrictions, it does so by facilitating treatment abroad rather than advocating for federal rescheduling or reform—potentially reinforcing the idea that U.S. regulatory barriers are insurmountable, delaying domestic access to innovation and reinforcing stigma around psychedelic-assisted therapies.
Rights & LibertiesPeopleRef: Sec. 1(3)
Who Is Most Affected
Adults with opioid use disorder—especially those with treatment-resistant forms—may gain access to a potentially transformative therapy if the study demonstrates strong efficacy. However, the requirement to travel to Mexico creates access barriers for low-income, disabled, or undocumented individuals, limiting who can actually benefit.
Addiction treatment providers (e.g., clinics, counselors, psychiatrists) may benefit from new evidence supporting alternative treatment pathways, but the bill does not fund implementation or provider training—so impact is limited to future policy or protocol changes, not immediate service expansion.
The University of Washington gains research leadership and prestige, but also assumes significant operational, ethical, and financial responsibility for an internationally complex study—potentially diverting staff and resources from other university health initiatives.
State agencies (e.g., DOH, DSHS) may benefit from new data to inform policy and funding decisions, but without mandated follow-up action or budget reallocation, the bill’s impact remains advisory—no direct authority or resources are granted.
Families and caregivers of people with opioid use disorder may benefit from reduced mortality and improved functioning of loved ones, but they bear no direct cost or risk and are not included in study design or implementation—making their benefit indirect and uncertain.